Wolfe F, Zhao S, Lane N
Arthritis Research Center and University of Kansas School of Medicine, Wichita 67214, USA.
Arthritis Rheum. 2000 Feb;43(2):378-85. doi: 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2.
Because there is controversy regarding the efficacy of acetaminophen in rheumatic diseases and because apparently safer nonsteroidal antiinflammatory drugs (NSAIDs) are being produced, we surveyed rheumatic disease patients about their preferences for these agents to determine the degree to which one type of therapeutic agent is preferred over the other.
In 1998, we surveyed by mailed questionnaire 1,799 patients with osteoarthritis (OA), rheumatoid arthritis, or fibromyalgia who were participating in a long-term outcome study. Patients who had taken acetaminophen rated the effectiveness of acetaminophen, compared its effectiveness with that of NSAIDs, and then rated their overall satisfaction with acetaminophen compared with NSAIDs when both effectiveness and side effects were considered.
Two-thirds of study participants had taken acetaminophen. About 37% of patients who had taken acetaminophen found it to be moderately or very effective and about 63% indicated that it was not effective or was only slightly effective. One-fourth of the patients found acetaminophen and NSAIDs to be equally effective, but >60% found acetaminophen to be much less effective or somewhat less effective. About 12% preferred acetaminophen to NSAIDs. When both effectiveness and side effects were considered together, 25% of the patients had no preference, 60% preferred NSAIDs, and 14% preferred acetaminophen.
There was a considerable and statistically significant preference for NSAIDs compared with acetaminophen among the 3 groups of rheumatic disease patients. Although this preference decreased slightly with age and was less pronounced in OA patients, the preference was noted among all categories of patients and was not altered by disease severity. If safety and cost are not issues, there would hardly ever be a reason to recommend acetaminophen over NSAIDs, since patients generally preferred NSAIDs and fewer than 14% preferred acetaminophen. If safety and costs are issues, then the recommendation of the American College Rheumatology that acetaminophen be tried first seems correct, since 38.2% found acetaminophen to be as effective or more effective than NSAIDs.
由于对乙酰氨基酚在风湿性疾病中的疗效存在争议,且明显更安全的非甾体抗炎药(NSAIDs)正在生产,我们对风湿性疾病患者进行了调查,了解他们对这些药物的偏好,以确定一种治疗药物比另一种更受青睐的程度。
1998年,我们通过邮寄问卷的方式对1799名骨关节炎(OA)、类风湿关节炎或纤维肌痛患者进行了调查,这些患者正在参与一项长期预后研究。服用过乙酰氨基酚的患者对乙酰氨基酚的有效性进行评分,将其有效性与非甾体抗炎药进行比较,然后在同时考虑有效性和副作用的情况下,对乙酰氨基酚与非甾体抗炎药的总体满意度进行评分。
三分之二的研究参与者服用过乙酰氨基酚。约37%服用过乙酰氨基酚的患者认为其有中度或非常有效的效果,约63%表示其无效或仅略有效果。四分之一的患者认为乙酰氨基酚和非甾体抗炎药同样有效,但超过60%的患者认为乙酰氨基酚效果差得多或略差。约12%的患者更喜欢乙酰氨基酚而非非甾体抗炎药。当同时考虑有效性和副作用时,25%的患者没有偏好,60%的患者更喜欢非甾体抗炎药,14%的患者更喜欢乙酰氨基酚。
在这三组风湿性疾病患者中,与乙酰氨基酚相比,对非甾体抗炎药有相当大且具有统计学意义的偏好。尽管这种偏好随年龄略有下降,在骨关节炎患者中不太明显,但在所有类别患者中都存在这种偏好,且不受疾病严重程度的影响。如果安全性和成本不是问题,几乎没有理由推荐使用乙酰氨基酚而非非甾体抗炎药,因为患者通常更喜欢非甾体抗炎药,只有不到14%的患者更喜欢乙酰氨基酚。如果安全性和成本是问题,那么美国风湿病学会建议首先尝试使用乙酰氨基酚似乎是正确的,因为38.2%的患者发现乙酰氨基酚与非甾体抗炎药一样有效或更有效。